Bolt Biotherapeutics (BOLT) replaces executive stock options at $5.44 per share

Rhea-AI Filing Summary

Bolt Biotherapeutics reported changes to a senior insider’s equity compensation on December 12, 2025. The reporting person is a director who also serves as President, CEO and CFO, and the transactions involve employee stock options to purchase common stock.

Several existing stock option grants with higher exercise prices were cancelled in exchange for new employee stock options with an exercise price of $5.44 per share. One of the options is fully vested and exercisable, while multiple new options vest in 36 monthly installments as long as the reporting person continues providing services, with vesting schedules starting from dates such as January 1, 2023, January 1, 2024, July 15, 2024, and January 1, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quinn William P.

(Last) (First) (Middle)

C/O BOLT BIOTHERAPEUTICS, INC.

900 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO and CFO

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		7,614		(1)	07/28/2030	Common Stock	7,614	(2)	7,614	D
Employee Stock Option (Right to Buy)	$56	12/12/2025		D			7,614	(1)	07/28/2030	Common Stock	7,614	(2)	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		3,927		(1)	09/02/2030	Common Stock	3,927	(3)	3,927	D
Employee Stock Option (Right to Buy)	$86.8	12/12/2025		D			3,927	(1)	09/02/2030	Common Stock	3,927	(3)	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		5,000		(1)	02/03/2031	Common Stock	5,000	(4)	5,000	D
Employee Stock Option (Right to Buy)	$400	12/12/2025		D			5,000	(1)	02/03/2031	Common Stock	5,000	(4)	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		10,499		(1)	02/17/2032	Common Stock	10,499	(5)	10,499	D
Employee Stock Option (Right to Buy)	$61.6	12/12/2025		D			10,499	(1)	02/17/2032	Common Stock	10,499	(5)	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		12,499		(6)	02/26/2033	Common Stock	12,499	(7)	12,499	D
Employee Stock Option (Right to Buy)	$31.8	12/12/2025		D			12,499	(6)	02/26/2033	Common Stock	12,499	(7)	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		11,749		(8)	03/03/2034	Common Stock	11,749	(9)	11,749	D
Employee Stock Option (Right to Buy)	$25.4	12/12/2025		D			11,749	(8)	03/03/2034	Common Stock	11,749	(9)	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		21,999		(10)	07/22/2034	Common Stock	21,999	(11)	21,999	D
Employee Stock Option (Right to Buy)	$14.602	12/12/2025		D			21,999	(10)	07/22/2034	Common Stock	21,999	(11)	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		34,999		(12)	04/30/2035	Common Stock	34,999	(13)	34,999	D
Employee Stock Option (Right to Buy)	$7.02	12/12/2025		D			34,999	(12)	04/30/2035	Common Stock	34,999	(13)	0	D

Explanation of Responses:

1. The option is fully vested and exercisable.

2. The reporting person agreed to cancellation of an option granted on July 29, 2020, in exchange for a new option having a lower price.

3. The reporting person agreed to cancellation of an option granted on September 3, 2020, in exchange for a new option having a lower exercise price.

4. The reporting person agreed to cancellation of an option granted on February 4, 2021, in exchange for a new option having a lower exercise price.

5. The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price.

6. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2023.

7. The reporting person agreed to cancellation of an option granted on February 27, 2023, in exchange for a new option having a lower exercise price.

8. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024.

9. The reporting person agreed to cancellation of an option granted on March 4, 2024, in exchange for a new option having a lower exercise price.

10. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024.

11. The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price.

12. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025.

13. The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price.

	/s/ William P. Quinn	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Bolt Biotherapeutics (BOLT) report in this Form 4 filing?

The filing reports that a senior insider at Bolt Biotherapeutics changed their equity compensation on December 12, 2025, cancelling several existing employee stock options and receiving new options to buy common stock.

Who is the reporting person in the Bolt Biotherapeutics (BOLT) Form 4 and what is their role?

The reporting person is a member of the board of directors and also an officer of Bolt Biotherapeutics, serving as President, CEO and CFO.

What type of securities were involved in the Bolt Biotherapeutics (BOLT) insider transaction?

The transactions involve employee stock options (rights to buy) that are exercisable for shares of Bolt Biotherapeutics common stock.

What is the exercise price of the new Bolt Biotherapeutics (BOLT) stock options?

The new employee stock options reported in the filing have an exercise price of $5.44 per share, replacing earlier options that had higher exercise prices.

What happened to the previously granted Bolt Biotherapeutics (BOLT) stock options?

The reporting person agreed to the cancellation of prior options granted on dates including July 29, 2020, September 3, 2020, February 4, 2021, February 18, 2022, February 27, 2023, March 4, 2024, July 23, 2024, and May 1, 2025, in exchange for new options with a lower exercise price.

How do the new Bolt Biotherapeutics (BOLT) stock options vest for the reporting person?

According to the filing, one option is fully vested and exercisable. Several other options vest in 1/36th monthly installments while the reporting person continues to provide services, with vesting beginning after dates such as January 1, 2023, January 1, 2024, July 15, 2024, and January 1, 2025.